Better than gold? $100,000 for US athletes who make the Winter Olympics and Paralympics

The stakes for all these U.S. skiers, skaters, snowboarders and sliders over the next 100 days could not be more clear. A ...

Yesavage and Jays dominate Dodgers in Game 5, one win away from World Series title

The Toronto Blue Jays are leaving Dodger Stadium with a 3-2 series lead over the reigning world champs, as Canada’s team is ...

'Yeah, boyeeee': Flavor Flav gives bobsled and skeleton a try, joins team as hype man for Olympics

Flavor Flav, the iconic rapper and reality star, has become the official hype man for the USA Bobsled and Skeleton team. The announcement came Monday after he spent time with ...

Dodgers’ Yamamoto stands as a formidable World Series obstacle to Jays

Yamamoto (3-1, 1.57 ERA) has been stellar in the postseason, as the Dodgers are trying to become MLB’s first repeat champions ...

Take it from the top: Toronto’s Trey Yesavage uses unusually high arm angle to his advantage

Trey Yesavage, a 22-year-old rookie for the Toronto Blue Jays, is getting attention with his unusual pitching style.

Scherzer doesn’t argue with Schneider, leaves World Series Game 3 with lead that bullpen wastes

Scherzer retired Andy Pages on a flyout, bringing up Shohei Ohtani, who doubled leading off the game and hit a solo home run ...

Yesavage pitches Blue Jays past Dodgers 6-1 for 3-2 lead in World Series

Trey Yesavage set a World Series rookie record with 12 strikeouts, and the Toronto Blue Jays opened Game 5 with back-to-back homers in a 6-1 victory over the Los Angeles Dodgers ...
pharmaphorum

Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...
pharmaphorum

FDA starts review of Sanofi's MS hope tolebrutinib

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis (MS) after a priority review by the US regulator. Tolebrutinib ...